Full Text View
Tabular View
No Study Results Posted
Related Studies
Alternate Day Buprenorphine Administration, Phase X - 15
This study has been completed.
Study NCT00000233   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: August 16, 2005   History of Changes

September 20, 1999
August 16, 2005
May 1993
 
  • Opioid withdrawal
  • Subjective dose estimate
  • Drug effect characteristics: ARCI
  • Money choice
Same as current
Complete list of historical versions of study NCT00000233 on ClinicalTrials.gov Archive Site
 
 
 
Alternate Day Buprenorphine Administration, Phase X - 15
Alternate Day Buprenorphine Administration, Phase X

The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.

 
Phase II
Interventional
Treatment
Opioid-Related Disorders
Drug: Buprenorphine
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Both
34 Years to 51 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000233
 
NIDA-06969-15, R01-06969-15
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
National Institute on Drug Abuse (NIDA)
September 1995

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP